相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat
Emma L. Lane et al.
BEHAVIOURAL BRAIN RESEARCH (2010)
l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia
Hanna S. Lindgren et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
ARCHIVES OF NEUROLOGY (2009)
The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease
Fabrizio Stocchi
PARKINSONISM & RELATED DISORDERS (2009)
Rodent models of treatment-induced motor complications in Parkinson's disease
M. Angela Cenci et al.
PARKINSONISM & RELATED DISORDERS (2009)
From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease
Peter Jenner
PARKINSONISM & RELATED DISORDERS (2009)
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism
Celia Larramendy et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat
Kristin B. Dupre et al.
PSYCHOPHARMACOLOGY (2008)
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat
Anna R. Carta et al.
SYNAPSE (2008)
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram
Wei-Li Kuan et al.
PSYCHOPHARMACOLOGY (2008)
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Robert A. Hauser et al.
MOVEMENT DISORDERS (2007)
Advances in understanding L-DOPA-induced dyskinesia
M. A. Cenci et al.
CURRENT OPINION IN NEUROBIOLOGY (2007)
The partial 5-HT1A agonist buspirone reduces the expression and development of I-DOPA-induced dyskinesia in rats and improves I-DOPA efficacy
Karen L. Eskow et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2007)
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease
Hai Zhang et al.
NEUROPHARMACOLOGY (2007)
Decreased expression of L-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets
Michael J. Jackson et al.
EXPERIMENTAL NEUROLOGY (2007)
Switching from levodopa to the long-acting dopamine D2/D3 agonist Piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates
Lance A. Smith et al.
CLINICAL NEUROPHARMACOLOGY (2006)
Developing a preclinical model of Parkinson's disease: A study of behaviour in rats with graded 6-OHDA lesions
L Truong et al.
BEHAVIOURAL BRAIN RESEARCH (2006)
Validation of the L-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists
C Monville et al.
BRAIN RESEARCH BULLETIN (2005)
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat
JL Taylor et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2005)
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors
T Carlsson et al.
BRAIN (2005)
Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias
MA Delfino et al.
BEHAVIOURAL BRAIN RESEARCH (2004)
Cabergoline - A review of its use in the treatment of Parkinson's disease
MP Curran et al.
DRUGS (2004)
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease - Final results of a 5-year, double-blind, Levodopa-controlled study
F Bracco et al.
CNS DRUGS (2004)
Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease
N Hattori
CURRENT OPINION IN NEUROLOGY (2003)
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)
EC Maratos et al.
EXPERIMENTAL NEUROLOGY (2003)
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease - An evidence-based comparison
R Inzelberg et al.
DRUGS & AGING (2003)
Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system
A Mura et al.
EXPERIMENTAL NEUROLOGY (2002)
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
M Lundblad et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Pergolide in the treatment of patients with early and advanced Parkinson's disease
U Bonuccelli et al.
CLINICAL NEUROPHARMACOLOGY (2002)
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)
EC Maratos et al.
MOVEMENT DISORDERS (2001)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats
C Reavill et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2000)
分享论文
